Fondaparinux Sodium for Anticoagulant Therapy After Primary Percutaneous Coronary Intervention: A Single-Center Randomized Trial in China.
Humans
Fondaparinux
/ therapeutic use
Percutaneous Coronary Intervention
/ adverse effects
Male
Female
Middle Aged
Aged
ST Elevation Myocardial Infarction
/ therapy
China
/ epidemiology
Treatment Outcome
Hemorrhage
/ chemically induced
Enoxaparin
/ adverse effects
Risk Factors
Time Factors
Anticoagulants
/ adverse effects
Factor Xa Inhibitors
/ adverse effects
Prospective Studies
Journal
Journal of cardiovascular pharmacology
ISSN: 1533-4023
Titre abrégé: J Cardiovasc Pharmacol
Pays: United States
ID NLM: 7902492
Informations de publication
Date de publication:
01 Sep 2024
01 Sep 2024
Historique:
received:
19
01
2024
accepted:
13
05
2024
medline:
6
9
2024
pubmed:
6
9
2024
entrez:
6
9
2024
Statut:
epublish
Résumé
In this study, we investigated the safety and efficacy of fondaparinux sodium in postpercutaneous coronary intervention (PCI) anticoagulation therapy for patients with ST-segment elevation myocardial infarction. There are a total of 200 patients with ST segment elevation myocardial infarction underwent PCI and anticoagulation therapy. They were randomly split into experimental (n = 108) and control groups (n = 92). The experimental group received postoperative fondaparinux sodium (2.5 mg q.d), while the control group received enoxaparin (4000 IU q12 h). We did not use a loading dose for enoxaparin. Bleeding incidence and major adverse cardiovascular/cerebrovascular events were monitored during hospitalization, and at 1, 3, and 6 months postsurgery. The primary end points, including bleeding, mortality, and myocardial infarction during hospitalization, were not significantly different between the 2 groups. For secondary end points, the incidence of combined end point events at 1 month, 3 months, and 6 months after surgery in the experimental group was lower than in the control group (P < 0.05). According to Cox regression analysis, the risk of bleeding in the experimental group was significantly lower than that in the control group [hazard ratios: 0.506, 95% confidence interval (CI): 0.284-0.900] (P = 0.020). The risk of mortality in the experimental group was significantly lower than in the control group (hazard ratio: 0.188, 95% CI: 0.040-0.889) (P = 0.035). In summary, perioperative use of fondaparinux sodium during PCI in patients with STEMI in this study was associated with a lower risk of bleeding and death compared with enoxaparin use in the absence of loading dose.
Identifiants
pubmed: 39240728
doi: 10.1097/FJC.0000000000001596
pii: 00005344-202409000-00007
doi:
Substances chimiques
Fondaparinux
J177FOW5JL
Enoxaparin
0
Anticoagulants
0
Factor Xa Inhibitors
0
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
331-339Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119–177.
Li J, Li X, Hu S, et al. ST-segment elevation myocardial infarction in the eastern urban China: from 2001 to 2011 [in Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi. 2016;44:303–308.
Kubo S, Yamaji K, Inohara T, et al. In-hospital outcomes after percutaneous coronary intervention for acute coronary syndrome with cardiogenic shock (from a Japanese Nationwide registry [J-PCI registry]). Am J Cardiol. 2019;123:1595–1601.
Türker Y. Role of tirofiban with dual antiplatelet therapy in patients with STEMI undergoing primary PCI. Anatol J Cardiol. 2015;15:956.
Kaymaz C, Keleş N, Özdemir N, et al. The effects of tirofiban infusion on clinical and angiographic outcomes of patients with STEMI undergoing primary PCI. Anatol J Cardiol. 2015;15:899–906.
Rao SV, Ohman EM. Anticoagulant therapy for percutaneous coronary intervention. Circ Cardiovasc Interv. 2010;3:80–88.
Ullrich H, Münzel T, Gori T. Coronary stent thrombosis—predictors and prevention. Dtsch Arztebl Int. 2020;117:320–326.
Bauer KA. New anticoagulants: anti IIa vs anti Xa—is one better? J Thromb Thrombolysis. 2006;21:67–72.
Leone G, Rossi E, Leone AM, et al. Novel antithrombotic agents: indirect synthetic inhibitors of factor Xa and direct thrombin inhibitors. Evidences from clinical studies. Curr Med Chem Cardiovasc Hematol Agents. 2004;2:311–326.
Walenga JM, Jeske WP, Samama MM, et al. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Expert Opin Investig Drugs. 2002;11:397–407.
Turpie AG, Bauer KA, Eriksson BI, et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002;162:1833–1840.
Warkentin TE, Davidson BL, Büller HR, et al. Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE. Chest. 2011;140:366–373.
Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354:1464–1476.
Xu ZX, Xia YM, Gao H, et al. Characteristics of traditional Chinese medicine syndrome in patients with coronary heart disease at different disease stages. World J Tradit Chin Med. 2022;8:218–224.
Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295:1519–1530.
FUTURA/OASIS-8 Trial Group, Steg PG, Jolly SS, Mehta SR, et al. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA. 2010;304:1339–1349.
Coussement PK, Bassand JP, Convens C, et al. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J. 2001;22:1716–1724.
Ray S, Shivdasani B, Mohan JC, et al. Clinical decision pathway for the use of fondaparinux in the management of acute coronary syndrome (ACS) in hospitals with and without catheter laboratories: an expert opinion from India. Cardiol Ther. 2023;12:261–274.
Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018) [in Polish]. Kardiol Pol. 2018;76:1383–1415.
Khoury S, Margolis G, Rozenbaum Z, et al. Acute renal impairment in older adults treated with percutaneous coronary intervention for ST-segment elevation myocardial infarction. Coron Artery Dis. 2019;30:564–568.
Song CX, Fu R, Yang JG, et al. Angiographic characteristics and in-hospital mortality among patients with ST-segment elevation myocardial infarction presenting without typical chest pain: an analysis of China Acute Myocardial Infarction registry. Chin Med J (Engl). 2019;132:2286–2291.
Bauer KA. Fondaparinux sodium: a selective inhibitor of factor Xa. Am J Health Syst Pharm. 2001;58(suppl 2):S14–S17.
Collet JP, Thiele H. The “Ten Commandments” for the 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020;41:3495–3497.
Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292:45–54.
Qiao J, Zhang X, Zhang J, et al. Comparison between fondaparinux and low-molecular-weight heparin in patients with acute coronary syndrome: a meta-analysis. Cardiology. 2016;133:163–172.
Silverio A, Galasso G, De Luca G. Consolidating the value of fondaparinux for current treatment of non-ST-elevation acute coronary syndromes. Int J Cardiol. 2021;335:21–23.
Hackett CT, Ramanathan RS, Malhotra K, et al. Safety of venous thromboembolism prophylaxis with fondaparinux in ischemic stroke. Thromb Res. 2015;135:249–254.
Simoons ML, Bobbink IW, Boland J, et al. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. J Am Coll Cardiol. 2004;43:2183–2190.